bluebird bio (NASDAQ:BLUE) will be issuing its quarterly earnings data after the market closes on Tuesday, February 20th. Analysts expect the company to announce earnings of ($1.68) per share for the quarter.
Shares of bluebird bio (BLUE) opened at $197.50 on Tuesday. bluebird bio has a 1 year low of $73.95 and a 1 year high of $222.03. The company has a market cap of $9,050.00, a PE ratio of -28.17 and a beta of 2.07.
BLUE has been the topic of several recent research reports. Wedbush reiterated an “outperform” rating and issued a $174.00 price objective (up from $135.00) on shares of bluebird bio in a research report on Thursday, November 2nd. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price on the stock in a report on Monday, October 16th. BMO Capital Markets upped their target price on shares of bluebird bio from $134.00 to $162.00 and gave the company a “buy” rating in a report on Monday, October 30th. Maxim Group set a $170.00 target price on shares of bluebird bio and gave the company a “buy” rating in a report on Friday, November 17th. Finally, BidaskClub lowered shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 16th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. bluebird bio presently has a consensus rating of “Hold” and an average price target of $161.45.
COPYRIGHT VIOLATION NOTICE: “bluebird bio (BLUE) to Release Quarterly Earnings on Tuesday” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/02/13/bluebird-bio-blue-to-release-quarterly-earnings-on-tuesday.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.